A study to optimize the dose of Idelalisib in Follicular Lymphoma

Update Il y a 4 ans
Reference: EUCTR2015-000366-66

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To optimize the safety and efficacy of chronic administration of idelalisib in subjects with follicular lymphoma (FL) who are randomized to treatment with idelalisib at 150 mg twice daily (BID) or 100 mg BID To evaluate the overall safety profile of idelalisib To evaluate the overall response rate (ORR) by Week 24


Inclusion criteria

  • Follicular lymphoma